Information från ABG Sundal Collier

Här finner du information kring börsens mindre och medelstora bolag. Avsändare är ABG Sundal Collier, innehållet är inte skapat av placera.nu:s redaktion.

« Tillbaka

Ogunsen - Holding margins through a soft market

22 maj 2026

<a id="bm-comp-c0873435-d8c7-4663-b9fb-bc5270a364dc" name="bm-comp-c0873435-d8c7-4663-b9fb-bc5270a364dc" class="BMCustomAnchor"></a><table><tr><td bm-component-id="c0873435-d8c7-4663-b9fb-bc5270a364dc" style="vertical-align: top; width:100.000000%;"><ul><li>Soft quarter, brighter outlook</li><li><font color="#000000">We raise our EBIT estimates by 3-2% for '26e-'27e</font></li><li>Early signs of a better market environment</li></ul></td></tr></table><a id="bm-comp-b38b0c1b-7963-4529-8b7f-931dafcf6e2a" name="bm-comp-b38b0c1b-7963-4529-8b7f-931dafcf6e2a" class="BMCustomAnchor"></a><table><tr><td bm-component-id="b38b0c1b-7963-4529-8b7f-931dafcf6e2a" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3">Q1'26 report</h3><p>Ogunsen reported Q1&#8217;26 sales of SEK 115m, down 2% y-o-y, reflecting lower hourly rates in the consulting segment and weaker demand in the recruitment segment. Sales were flat in the consulting segment at SEK 106m, and now correspond to 93% of total sales. The recruiting segment has historically been affected by weaker demand, and Q1 sales decreased by 18% to SEK 8m. Even if the top-line remains soft due to weaker demand in the market, Ogunsen kept adj. EBIT flat at SEK 6m (SEK 6m in Q1&#8217;25) and came in above our expectations at SEK 5m, with a margin of 5.3% (5.2% in Q1'25 adjusted for one-off costs last year), supported by a leaner organisation and AI-driven efficiency, which we expect to support margins going forward.</p><h3 class="bm-h3">Slightly increased EBIT estimates</h3><p>After years of a declining consulting market alongside headwinds from lower demand and pricing pressure, we think that market conditions are slowly showing early signs of easing. As such, we slightly raise our '26e-'27e EBIT estimates by 3-2%.</p><h3 class="bm-h3">Trading at 10x/8x EV/EBIT for '26e/'27e</h3><p>Ogunsen is trading at 10x/8x EV/EBIT for &#8217;26e/&#8217;27e and is well-positioned to benefit from improving market conditions in H2&#8217;26. Consulting volumes are slightly rising and should support sales as pricing recovers, while early signs of somewhat stronger recruitment demand could add upside in the longer term given the segment&#8217;s high margins, driving earnings into next year.</p></td></tr></table>

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-07-14 Nexam Chemical - Solid Q2, profitability within r... Nexam Chemical Analys
2026-07-14 Nexam Chemical - Record sales and first positive ... Nexam Chemical Analys
2026-07-14 Eastnine - Warsaw to become the largest market Eastnine Analys
2026-07-13 Ascelia Pharma - CRL update Ascelia Pharma Analys
2026-07-13 Medicover - Steady as she goes Medicover Analys
2026-07-13 Arctic Paper - Pulp beats paper Arctic Paper Analys
2026-07-13 Studsvik - Gearing up for the new-build era Studsvik Analys
2026-07-10 StrongPoint - The American dream StrongPoint Analys
2026-07-10 Careium - The pressure valve starting to open Careium Analys
2026-07-10 StrongPoint - Solid Q2 performance StrongPoint Analys
2026-07-10 Careium - Growth's comeback tour continues Careium Analys
2026-07-09 Infrea - Road tripping with Netel Infrea Analys
2026-07-08 Alligo - Softer growth, but margin recovery conti... Alligo Analys
2026-07-08 Qliro - Key earnings drivers intact Qliro Analys
2026-07-07 Nexam Chemical - We expect a firmer sequential qu... Nexam Chemical Analys
2026-07-07 Eastnine - Adding in Warsaw Eastnine Analys
2026-07-06 Ovzon - No Q2 fireworks, but plenty of fuel Ovzon Analys
2026-07-05 StrongPoint - Steady through the transition StrongPoint Analys
2026-07-03 Ascelia Pharma - Complete Response Letter for Orv... Ascelia Pharma Analys
2026-07-03 Fastpartner - Positive development on IFPM guidan... Fastpartner Analys